Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06030427
Other study ID # 23-004890
Secondary ID NCI-2023-0640723
Status Recruiting
Phase N/A
First received
Last updated
Start date September 8, 2023
Est. completion date October 2024

Study information

Verified date January 2024
Source Mayo Clinic
Contact Moua Torgerson
Phone 608-392-9142
Email torgerson.moua@mayo.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial tests how well a virtual mindfulness and weight management program to mitigate risk of relapse and improve well being for obese cancer survivors in community practice and rural areas. Obesity has been linked to increased risk for certain kinds of cancer and is the second highest modifiable risk factor for cancer. It is also well documented that having a cancer diagnosis and treatment is a stressful experience. It is hoped that an addition of a 10-minute mindfulness-based stress reduction exercise to the virtual positive health habits group focused on weight management can improve wellbeing and distress. Virtual care options continue to extend the reach of medical providers to cancer survivors, particularly those in the rural setting. A virtual behavioral weight management program with an integrated mindfulness component may improve mood, coping strategies, stress management, and weight loss among community practice and rural obese cancer survivors.


Description:

PRIMARY OBJECTIVES: I. To assess if a 12-week virtual weight management program with a mindfulness component will improve well-being of obese cancer patients with a specific focus on self-reported measures of depression and anxiety. II. To assess if a mindfulness component added to the virtual behavioral weight management will promote weight loss, improve mood, and increase physical activity. OUTLINE: Patients participate in a virtual behavioral weight management program with an integrated mindfulness component consisting of 12, 75-minute virtual group sessions over 12 weeks to help improve mood, coping strategies, stress management, and weight loss. Patents also receive patient education handouts, view behavioral educational PowerPoint presentations over 30 minutes, and wear a Fitbit on study.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date October 2024
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 or over - Identified stage I, II, or III cancer in remission - Body mass index (BMI) of 30 or greater - English as a primary language - Has access to a device with a camera (computer, tablet, or video capable phone) that has wifi and reliable internet access Exclusion Criteria: - Unable to provide consent - Eastern Cooperative Oncology Group (ECOG) performance status scale score of 3 or above

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Behavioral Dietary Intervention
Participate in weight management program
Other:
Educational Intervention
Receive patient education handouts
Health Promotion and Education
View behavioral educational PowerPoint presentation
Internet-Based Intervention
Complete virtual behavioral weight management with an integrated mindfulness component program
Interview
Ancillary studies
Medical Device Usage and Evaluation
Wear Fitbit
Behavioral:
Mindfulness Relaxation
Complete mindfulness components
Other:
Physical Performance Testing
Ancillary studies
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States Mayo Clinic Health System-Franciscan Healthcare La Crosse Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary General anxiety disorder-7 (GAD-7) Assessed by change in GAD-7 scores from a total score for seven items ranges from 0 to 21: 0-4 (minimal anxiety); 5-9 (mild anxiety); 10-14 (moderate anxiety); 15-21 (severe anxiety). Baseline; 12 weeks
Primary Patient Health Questionnaire (PHQ)-8 Assessed by change in PHQ-8 scores, as measured by a total score of 4 items from 0-12: 0-2 (normal); 3-5 (mild depression); 6-8 (moderate depression); 9-12 (severe depression). Baseline; 12 weeks
Primary Feasibility of virtual mindfulness and weight management program Assessed by the extent to which participants adhere to the intervention. Will be quantified based on number of sessions attended out of a possible 12. 12 weeks
Secondary Body weight Assessed by change in body weight Baseline; 12 weeks
Secondary Body composition parameter Will be assessed in a fasted state or 3 hour post meal by subjects standing on a scale without socks or shoes. Baseline; 12 weeks
Secondary Daily activity levels - heart rate Will be assessed by heart rate monitoring as recorded by a wrist-worn accelerometer (Fitbit Inspire) Baseline; 12 weeks
Secondary Daily activity levels - activity Will be assessed from data recorded by a wrist-worn accelerometer monitoring fitness activity. Baseline; 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT05660421 - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Phase 2
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT06192875 - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Completed NCT04122118 - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor N/A
Active, not recruiting NCT04940299 - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Phase 2
Active, not recruiting NCT03168737 - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients Phase 1
Active, not recruiting NCT06062901 - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors N/A
Active, not recruiting NCT02444741 - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT04081298 - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors N/A
Active, not recruiting NCT04555837 - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Completed NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Phase 2
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Recruiting NCT04871542 - Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Active, not recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT05112614 - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Recruiting NCT05873608 - Communication Issues in Patient and Provider Discussions of Immunotherapy N/A
Recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A
Recruiting NCT05372614 - Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene Phase 1

External Links